Activation of gp130 signaling in T cells drives T(H)17-mediated multi-organ autoimmunity

The IL-6-gp130-STAT3 signaling axis is a major regulator of inflammation. Activating mutations in the gene encoding gp130 and germline gain-of-function mutations in STAT3 (STAT3(GOF)) are associated with multi-organ autoimmunity, severe morbidity, and adverse prognosis. To dissect crucial cellular subsets and disease biology involved in activated gp130 signaling, the gp130-JAK-STAT3 axis was constitutively activated using a transgene, L-gp130, specifically targeted to T cells. Activating gp130 signaling in T cells in vivo resulted in fatal, early onset, multi-organ autoimmunity in mice that resembled human STAT3(GOF) disease. Female mice had more rapid disease progression than male mice. On a cellular level, gp130 signaling induced the activation and effector cell differentiation of T cells, promoted the expansion of T helper type 17 (T(H)17) cells, and impaired the activity of regulatory T cells. Transcriptomic profiling of CD4(+) and CD8(+) T cells from these mice revealed commonly dysregulated genes and a gene signature that, when applied to human transcriptomic data, improved the segregation of patients with transcriptionally diverse STAT3(GOF) mutations from healthy controls. The findings demonstrate that increased gp130-STAT3 signaling leads to T(H)17-driven autoimmunity that phenotypically resembles human STAT3(GOF) disease.